tiprankstipranks
Pacific Biosciences (PACB)
NASDAQ:PACB
US Market
Want to see PACB full AI Analyst Report?

Pacific Biosciences (PACB) Remaining Performance Obligations

2,877 Followers

Remaining Performance Obligations

Represents contracted but unrecognized revenue from instrument orders, service agreements, and reagent commitments, giving visibility into near‑term booked revenue. Large RPOs suggest strong forward sales and revenue certainty; shrinking RPOs can warn of weakening demand or cancellations.
RPO has trended down since late‑2024 with a pronounced drop in mid‑2025 and continued softness into Q1‑2026, reflecting weaker forward bookings and reduced near‑term revenue visibility—consistent with the lowered 2026 guide and softer instrument demand from promotions, APAC delays and delivery disruptions. Offsetting this, record consumables, improving Revio pull‑through and the SPRQ‑Nx commercial launch create a plausible path to rebuild backlog if adoption converts; however promotional ASPs, compute‑cost pressure and funding headwinds could keep RPO subdued.
Date
Remaining Performance Obligations
Jun 30, 2026
$47.90M
Mar 31, 2026
$46.60M
Dec 31, 2025
$49.20M
Sep 30, 2025
$48.70M
Jun 30, 2025
$56.60M
Mar 31, 2025
$58.70M
Dec 31, 2024
$58.60M